oLAB ELISA (Anti oxidized LDL autoantibodies)

Catalog number: BI-20032
Brand: Biomedica
Packing: 96 tests
Price: On Request
Expected delivery time: 7 days
Quantity:

Product specifications for - oLAB ELISA (Anti oxidized LDL autoantibodies)

Overview: 
Product group: Assays
Category: ELISA / EIA
Application note: ELISA
Reactivity note: human
Properties: 
Assay Sensitivity: 48 mU/ml
Assay Specificity: Anti-oxidized LDL autoantibodies
Assay Precision: intra-assay: 4%, inter-assay: 8%
Assay Sample Type: Serum
Assay Time: 90 min / 30 min / 15 min
Assay Detection Range: 48-1200 mU/ml
Datasheet: Datasheet
  Research Use Only
UNSPSC: 41116133
Scientific information: 
Scientific info: The Biomedica oLAB Sandwich ELISA kit is a test that is intended for the quantitative measurement of autoantibodies against oxidised LDL levels in human serum. The ELISA is CE certified and approved for in-vitro diagnostic use in the EU.Target information:Oxidized low density lipoprotein (oxLDL) is believed to play a critical role in the development and progression of atherosclerosis. Accumulation of oxLDL in macrophages and smooth muscle cells causes foam cell formation, an initial step in the disease. Autoantibodies against oxidatively modified LDL can be used as a parameter that consistently mirrors the occurrence of oxidation processes taking place in vivo. In fact, elevated levels of autoantibodies against oxLDL have been detected in the blood stream of patients with coronary artery disease. Moreover, recent studies indicate a correlation between autoantibodies against oxLDL and the progression of carotid atherosclerosis. Increased serum concentrations of oLAB have also been described in various diseases such as pre-eclampsia and systemic lupus erythematosus. Decreased oLAB titers were observed during septicemia and myocardial infarction.
Safety information: 
MSDS: MSDS
Additional information: 
Synonyms: BI-20032; Biomedica Gruppe
de Freitas ACP et al., “Is oxidized low-density lipoprotein the connection between atherosclerosis, cardiovascular risk and nephrolithiasis?" Urolithiasis. (2019); 47(4):347-356. Read more
Díaz-Ruiz M et al., “Metabolic disorders and inflammation are associated with familial combined hyperlipemia.” Clin Chim Acta. (2019) 490:194-199. Read more
Arifin R et al., “Increased circulating oxidised low-density lipoprotein and antibodies to oxidised low-density lipoprotein in preeclampsia.” J Obstet Gynaecol. (2017) 37(5):580-584. Read more
All Citations Read more